Perfusion magnetic resonance imaging: Comparison of semiologic characteristics in first-pass perfusion of brain tumors at 1.5 and 3 Tesla

Journal of Neuroradiology

Volumn 39, Issue 5, 2012, Pages 308-316

  Mauz, Natacha ^a   Krainik, Alexandre ^a   Tropres, Irène ^b   Lamalle, Laurent ^b   Sellier, Elodie ^a   Eker, Omer ^a   Tahon, Florence ^a   Le Bas, Jean François ^a   Grand, Sylvie ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

1.5T; 3T; Brain tumors; MRI; Perfusion

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN TUMOR; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MICROVASCULAR LEAKAGE; PERFUSION WEIGHTED IMAGING; PROSPECTIVE STUDY; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BRAIN NEOPLASMS; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84870654724     PISSN: 01509861     EISSN: 17730406     Source Type: Journal    
DOI: 10.1016/j.neurad.2011.12.004     Document Type: Article

References (29)

1. *-weighted MR imaging. Radiology 1999, 211:791-798.
2. Wong J., Provenzale J., Petrella J. Perfusion MR imaging of brain neoplasms. Am J Roentgenol 2000, 174:1147-1157.
3. Rollin N., Guyotat J., Streichenberger N., Honnorat J., Tian Minh V., Cotton F. Clinical relevance of diffusion and perfusion MRI in assessing intra-axial brain tumors. Neuroradiology 2006, 48:150-159.
4. Weber M., Zoubaa S., Schlieter M., et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006, 66:1899-1906.
5. Cotton F., Ongolo-Zogo P., Louis-Tisserand G., et al. IRM de diffusion-perfusion dans l'évaluation des lymphomes cérébraux. J Neuroradiol 2006, 33:220-228.
6. Hartmann M., Heiland S., Harting I., et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003, 338:119-122.
7. Bing F., Kremer S., Lamalle L., et al. Value of perfusion MRI in the study of pilocytic astrocytoma and hemangioblastoma: preliminary findings. J Neuroradiol 2009, 36:82-87.
8. Law M., Yang S., Babb J., et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 2004, 25:746-755.
9. Lev M., Ozsunar Y., Henson J., et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced. MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 2004, 25:214-221.
10. Roberts H., Roberts T., Brasch R., Dillon W. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. Am J Neuroradiol 2000, 21:891-899.
11. Jiang Z., Le Bas J., Grand S., et al. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: a survival study. J Neuroradiol 2011, 38:53-61.
12. Price S., Green H., Dean A., Joseph J., Hutchinson P., Gillard J. Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. Am J Neuroradiol 2011, 32:501-506.
13. Dhermain F., Hau P., Lanfermann H., Jacobs A., van den Bent M. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010, 9:906-920.
14. Wattjes M., Lutterbey G., Harzheim M., et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5T with 3.0T. Eur Radiol 2006, 16:2067-2073.
15. Notohamiprodjo M., Dietrich O., Horger W., et al. Diffusion tensor imaging (DTI) of the kidney at 3 tesla-feasibility, protocol evaluation and comparison to 1,5 tesla. Invest Radiol 2010, 45:245-254.
16. Sjobakk T., Lundgren S., Kristoffersen A., et al. Clinical 1H magnetic resonance spectroscopy of brain metastases at 1.5T and 3T. Acta Radiol 2006, 47:501-508.
17. Kamada K., Kakeda S., Ohnari N., Moriya J., Sato T., Korogi Y. Signal intensity of motor and sensory cortices on T2-weighted and FLAIR images: intraindividual comparison of 1.5T and 3T MRI. Eur Radiol 2008, 18:2949-2955.
18. Keihaninejad S., Heckemann R., Fagiolo G., Symms M., Hajnal J., Hammers A. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010, 50:1427-1437.
19. Stankiewicz J.M., Glanz B.I., Healy B.C., et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging 2011, 21:e50-e56.
20. Zaharchuk G. Theoretical basis of heomdynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. Am J Neuroradiol 2007, 28:1850-1858.
21. Cha S., Lupo J., Chen M., et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007, 28:1078-1084.
22. Mangla R., Kolar B., Zhu T., Zhong J., Almast J., Ekholm S. Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. Am J Neuroradiol 2011, [Epub ahead of print].
23. Law M., Young R.J., Babb J.S., et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008, 247:490-498.
24. Chiang I., Kuo Y., Lu C., et al. Distinction between high-grade gliomas and solitary metastasis using peritumoral 3T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004, 46:619-627.
25. Holmes T., Petrella J., Provenzale J. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. Am J Roentgenol 2004, 183:1247-1252.
26. * and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol 2006, 16:2083-2091.
27. Vonken E., van Osch M., Bakker C., Viergever M. Simultaneously quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI. Magn Reson Med 2000, 43:820-827.
28. * shortening in contrast-enhanced MRI of the breast. J Magn Reson Imag 1999, 9:172-176.
29. Boxerman J., Schmainda K., Weisskoff R. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol 2006, 25:259-267.